“Development Plan” shall mean a development plan outlining the non–clinical and clinical development plans and CMC plans for the Drug Product to meet the criteria of the TPP, which Development Plan is attached as Schedule 1 hereto, as amended from time to time in accordance with the terms of this Agreement;
“Regulatory Plan” shall mean a regulatory plan outlining the regulatory strategy for obtaining Marketing Authorisations for the Drug Product and split of regulatory responsibilities of the Parties with the aim of ensuring equitable and affordable access to the Product for people in the DNDi Territory and the Entasis Territory at the earliest possible date, as further described in Schedule 4 hereto and in Clause 5, as may be amended from time to time.
4. Development of the Drug Product
4.1 The Parties shall use commercially reasonable endeavours to develop the Drug Product in the Field in accordance with this Clause 4, the Development Plan and the Regulatory Plan.
6. Product Manufacture and Supply
6.1 Within six (6) months of the Effective Date or such longer period as may otherwise be agreed in writing (including by email), the Parties shall agree a detailed Manufacturing and Supply Plan for the supply of the Drug Product through the JSC. The Manufacturing and Supply Plan shall be based on the following principles:
6.1.1 the Parties shall develop a detailed forecasting, supply, access and implementation plan for the supply of the Drug Product and define related operational supply chain management processes to ensure availability and access of the Drug Product in the Field with the consultation, as appropriate, of one or more funding agencies or partners, e.g., the World Health Organisation;
[…]
6.1.7 each Party will use commercially reasonable endeavours to ensure that the Drug Product is made available at price which is affordable and sustainable in its respective Territory and any part thereof;
Charles B. Holmes, MD, MPH, FIDSA, a physician and global health leader with more than 25 years of experience, brings expertise in public health policy, strengthening health systems, and the introduction and scale-up of health innovations. As Director of the Center for Innovation in Global Health at Georgetown University and Senior Advisor to Gates Medical Research Institute, he works at the intersection of science, policy, and implementation to improve health outcomes globally. His leadership experience includes serving as Chief Medical Officer and Deputy U.S. Global AIDS Coordinator at PEPFAR, Chief Executive Officer of CIDRZ in Zambia, and senior roles across academia, government, and industry. His experience building partnerships across countries, institutions, and sectors positions him to support GHIAA’s mission of advancing equitable and sustainable access to health innovations worldwide.
Sign Up to Our Newsletter
Receive updates about GHIAA’s latest tools, resources and news.
